Thyroid medicine recalled nationwide: FDA

Major Pharmaceuticals has initiated a nationwide recall of its Levothyroxine Sodium tablets. Federal regulators at the Food and Drug Administration classified this action as a Class II recall. This classification indicates that the medication is subpotent and may not provide the full therapeutic effect required to treat conditions such as hypothyroidism and goiter.

The recall process began on July 13, 2026. The affected tablets were distributed by Major Pharmaceuticals and Cardinal Health throughout the United States. These products were packaged in 10-count blister packs and sold in various configurations including individual packs or cartons containing 100 total tablets.

Patients should check their medication for specific dosage strengths ranging from 25 to 150 micrograms. The recalled batches have expiration dates between July 2026 and January 2027. While the FDA did not state the total number of affected units, the agency maintains that these medications may result in temporary adverse health outcomes for users.

Individuals who use this thyroid medication are encouraged to verify their pill packaging against the recall notice details. Those with concerns about their treatment or the effectiveness of their current supply should consult with their healthcare provider immediately to discuss alternatives or next steps.